KMT2A and acute myeloid leukemia: In early clinical trials, monotherapy with MI is well tolerated and has achieved objective remissions in patients with previously treated relapsed/refractory AML harboring MLL1-r or NPM1c, highlighting the promising on-target activity of MI on AML expressing MLL-FP or NPM1c [5, 21, 22].